Genetically Predicted Insomnia in Relation to 14 Cardiovascular Conditions and 17 Cardiometabolic Risk Factors: A Mendelian Randomization Study.
Xinhui Liu,Chuanbao Li,Xiaoru Sun,Yuanyuan Yu,Shucheng Si,Lei Hou,Ran Yan,Yifan Yu,Mingzhuo Li,Hongkai Li,Fuzhong Xue
DOI: https://doi.org/10.1161/jaha.120.020187
IF: 6.106
2021-07-30
Journal of the American Heart Association
Abstract:Background This Mendelian randomization study aims to investigate causal associations between genetically predicted insomnia and 14 cardiovascular diseases (CVDs) as well as the potential mediator role of 17 cardiometabolic risk factors. Methods and Results Using genetic association estimates from large genome‐wide association studies and UK Biobank, we performed a 2‐sample Mendelian randomization analysis to estimate the associations of insomnia with 14 CVD conditions in the primary analysis. Then mediation analysis was conducted to explore the potential mediator role of 17 cardiometabolic risk factors using a network Mendelian randomization design. After correcting for multiple testing, genetically predicted insomnia was consistent significantly positively associated with 9 of 14 CVDs, those odds ratios ranged from 1.13 (95% CI, 1.08–1.18) for atrial fibrillation to 1.24 (95% CI, 1.16–1.32) for heart failure. Moreover, genetically predicted insomnia was consistently associated with higher body mass index, triglycerides, and lower high‐density lipoprotein cholesterol, each of which may act as a mediator in the causal pathway from insomnia to several CVD outcomes. Additionally, we found very little evidence to support a causal link between insomnia with abdominal aortic aneurysm, thoracic aortic aneurysm, total cholesterol, low‐density lipoprotein cholesterol, glycemic traits, renal function, and heart rate increase during exercise. Finally, we found no evidence of causal associations of genetically predicted body mass index, high‐density lipoprotein cholesterol, or triglycerides on insomnia. Conclusions This study provides evidence that insomnia is associated with 9 of 14 CVD outcomes, some of which may be partially mediated by 1 or more of higher body mass index, triglycerides, and lower high‐density lipoprotein cholesterol. Nonstandard Abbreviations and Acronyms IS ischemic stroke IVW inverse variance weighted MR Mendelian randomization WC waist circumference WHR waist‐hip ratio Clinical Perspective What Is New? Insomnia is the second most prevalent mental disorder. Except for some major cardiovascular diseases (CVDs), the causal relationships between insomnia and the development of other CVDs such as arterial hypertension are still unclear, and the potential pathways involved in the association from insomnia to CVDs have not been studied. This study performed Mendelian randomization analysis to investigate the causal associations between genetically predicted insomnia and 14 CVDs as well as the potential mediator role of 17 cardiometabolic risk factors. What Are the Clinical Implications? Insomnia was found to increase the risk of 9 of 14 CVD outcomes, including ischemic stroke, transient ischemic attack, thrombotic diseases, and 5 other CVDs (eg, coronary artery disease, heart failure, arterial hypertension). Genetic predicted insomnia was associated with higher body mass index and triglycerides as well as lower high‐density lipoprotein cholesterol (without bidirectional causality), each of which may act as a mediator in the causal pathway from insomnia to several CVD outcomes. These results are consistent with previous studies that suggest insomnia as an important causal risk factor for some major CVDs. Insomnia is the second most prevalent mental disorder with an annual incidence of approximately 35% to 50% in the general population. 1 , 2 In the past decade, there has been increasing evidence suggesting insomnia as an important risk factor of cardiovascular disease (CVD), 3 , 4 , 5 , 6 but evidence originating from observational studies (eg, the association between insomnia and h -Abstract Truncated-
cardiac & cardiovascular systems